Animal Carcinogenesis Core - Developmental Funds
动物致癌核心 - 发展基金
基本信息
- 批准号:8369407
- 负责人:
- 金额:$ 6.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-07-01 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Developmental funds are instrumental in supporting faculty recruitment bridge funding, pilot project funding and the establishment of the new Animal Carcinogenesis Core at the University of Hawai'i Cancer Center (UHCC). Achieving the mission and long-term goals UHCC is dependent upon the ability to recruit the highest caliber scientists with clinical, basic, behavioral, epidemiological expertise who can lead high impact investigator initiated research, strengthen research collaborations among members of the Hawai'i Cancer Consortium (HCC), and advance the translational research agenda of UHCC. In the current grant cycle limited CCSG funds were available for use as developmental funds and a majority of the funds were used for strategic recruitments, including the recruitment of Dr. Michele Carbone in 2006, who is now the Director of UHCC. CCSG Developmental Funds were used to support 2 additional recruitments - Dr. Iona Cheng, who is the recipient of a V Foundation award and 2 R01 grants and Dr. Unhee Lim, who was awarded an AICR grant. Bridge funding will provide support for interim salaries and research support for promising investigators. Pilot grants will enable the development of new collaborative initiatives. The newly proposed Animal Carcinogenesis Core will enhance UHCC opportunities to utilize state-of-art animal models for translational cancer research, a murine tumor tissue bank, and expert consultation regarding animal experiments. CCSG developmental funds will ultimately continue to help UHCC leverage significant institutional and philanthropic support, a portion of which has been invested into providing pilot funding and bridge funding to UHCC faculty, many of which have led to new or renewal R01 or equivalent NCI-approved cancer-focused funding. The past success of the CCSG and institutional Developmental Funds reflects the sound leadership of and oversight mechanisms in place to ensure appropriate use.
发展基金有助于在夏威夷大学癌症中心(UHCC)(UHCC)建立新的动物致癌核心,并建立新的动物致癌核心。实现任务和长期目标UHCC取决于具有临床,基本,行为,流行病学专业知识的招募最高才能的科学家的能力,他们可以领导高影响力研究者开始研究,加强了夏威夷癌症联盟(HCC)成员之间的研究合作,并提高了UHCC的转化研究议程。在当前的赠款周期有限公司中,CCSG资金可用作开发基金,大多数资金用于战略招聘,包括2006年招募Michele Carbone博士,现在是UHCC董事。 CCSG开发基金用于支持另外2项招聘-Iona Cheng博士,他是V基金会奖的获得者和2份R01赠款和未获得AICR赠款的Unnee Lim博士。桥梁资金将为有前途的调查人员提供临时薪水和研究支持。飞行员赠款将实现新的合作计划的发展。新提出的动物癌变核心将增加UHCC的机会,利用最先进的动物模型进行转化癌症研究,鼠肿瘤组织库以及有关动物实验的专家咨询。 CCSG开发基金最终将继续帮助UHCC利用大量的机构和慈善支持,其中一部分已投资用于向UHCC教师提供飞行员资金和桥梁资金,其中许多导致了新的或更新的R01或等效的NCI-NCI-NCI-NCI-NCI-IP-NCI-appercred批准的癌症。 CCSG和机构发展基金的过去成功反映了确保适当使用的机制和监督机制的合理领导。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
MICHELE CARBONE的其他基金
Influence of germline mutations on susceptibility to environmental carcinogens
种系突变对环境致癌物易感性的影响
- 批准号:1021239010212390
- 财政年份:2019
- 资助金额:$ 6.17万$ 6.17万
- 项目类别:
Mechanisms of BAP1 activity in human cancer development
BAP1 活性在人类癌症发展中的机制
- 批准号:98881809888180
- 财政年份:2019
- 资助金额:$ 6.17万$ 6.17万
- 项目类别:
Mechanisms of BAP1 activity in human cancer development
BAP1 活性在人类癌症发展中的机制
- 批准号:1052843710528437
- 财政年份:2019
- 资助金额:$ 6.17万$ 6.17万
- 项目类别:
Mechanisms of BAP1 activity in human cancer development
BAP1 活性在人类癌症发展中的机制
- 批准号:1030490510304905
- 财政年份:2019
- 资助金额:$ 6.17万$ 6.17万
- 项目类别:
Germline BAP1 Mutations and Malignant Mesothelioma: Mechanisms and Early Detection
种系 BAP1 突变和恶性间皮瘤:机制和早期检测
- 批准号:92949959294995
- 财政年份:2015
- 资助金额:$ 6.17万$ 6.17万
- 项目类别:
Germline BAP1 Mutations and Malignant Mesothelioma: Mechanisms and Early Detection
种系 BAP1 突变和恶性间皮瘤:机制和早期检测
- 批准号:91057289105728
- 财政年份:2015
- 资助金额:$ 6.17万$ 6.17万
- 项目类别:
Biostatistics and Informatics Shared Resource
生物统计学和信息学共享资源
- 批准号:83693998369399
- 财政年份:2012
- 资助金额:$ 6.17万$ 6.17万
- 项目类别:
相似国自然基金
菌根真菌介导的同种密度制约对亚热带森林群落物种共存的影响
- 批准号:32371600
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
B7H4-LILRB4信号调控B细胞代谢重编程机制在同种抗体产生及防治AMR中的作用
- 批准号:82371792
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
利用HERV-K(HML-2)多态性探讨不同种族群体的遗传多样性和疾病易感性差异
- 批准号:32200491
- 批准年份:2022
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
抗骨髓瘤的新型同种异体嵌合抗原受体T(CAR T)细胞疗法研发
- 批准号:82270210
- 批准年份:2022
- 资助金额:68 万元
- 项目类别:面上项目
利用HERV-K(HML-2)多态性探讨不同种族群体的遗传多样性和疾病易感性差异
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Animal Carcinogenesis Core - Developmental Funds
动物致癌核心 - 发展基金
- 批准号:87361348736134
- 财政年份:
- 资助金额:$ 6.17万$ 6.17万
- 项目类别:
Animal Carcinogenesis Core - Developmental Funds
动物致癌核心 - 发展基金
- 批准号:87243598724359
- 财政年份:
- 资助金额:$ 6.17万$ 6.17万
- 项目类别:
Animal Carcinogenesis Core - Developmental Funds
动物致癌核心 - 发展基金
- 批准号:87243918724391
- 财政年份:
- 资助金额:$ 6.17万$ 6.17万
- 项目类别:
Animal Carcinogenesis Core - Developmental Funds
动物致癌核心 - 发展基金
- 批准号:85659518565951
- 财政年份:
- 资助金额:$ 6.17万$ 6.17万
- 项目类别:
Animal Carcinogenesis Core - Developmental Funds
动物致癌核心 - 发展基金
- 批准号:87243928724392
- 财政年份:
- 资助金额:$ 6.17万$ 6.17万
- 项目类别: